diphenylamine has been researched along with Adenocarcinoma, Basal Cell in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, HJ; Go, YH; Hong, SK; Kwon, OS; Kwon, SJ; Oh, E | 1 |
| Dankort, D; Green, S; Juan, J; McMahon, M; Shai, A | 1 |
| Bazhenova, L; Cohen, RB; Eisenberg, PD; Gadgeel, SM; Haura, EB; Larson, TG; Miller, VA; Ricart, AD; Selaru, P; Stella, PJ; Wilner, KD | 1 |
| Chitale, D; Fagin, JA; Halilovic, E; Heguy, A; Huberman, K; Janakiraman, M; Jhanwar, SC; Ladanyi, M; Lash, A; Levine, DA; Mariadason, JM; Paty, PB; Persaud, Y; Pratilas, CA; Ricarte Filho, JC; Saltz, LB; Solit, DB; Taylor, BS; Vakiani, E; Wilson, M; Zeng, Z | 1 |
| Juan, J; McMahon, M; Sweet-Cordero, A; Trejo, CL; Vicent, S | 1 |
| Christensen, JG; Eswaraka, J; Giddabasappa, A; Kan, JL; Lalwani, K; Lappin, PB; Lee, JH; Shojaei, F; Simmons, BH; Snider, BA; Wong, A | 1 |
| Chandrasekaran, V; Katayama, S; Weisburger, JH; Williams, GM | 1 |
| Fiala, E; Katayama, S; Reddy, BS; Rivenson, A; Silverman, J; Weisburger, JH; Williams, GM | 1 |
1 trial(s) available for diphenylamine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzamides; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diphenylamine; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
7 other study(ies) available for diphenylamine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biphenyl Compounds; Cell Proliferation; Cell Survival; Chemoradiotherapy; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Molecular Mimicry; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Signal Transduction; Sulfonamides; Transfection; Up-Regulation | 2017 |
TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
Topics: Adenocarcinoma; Adenoma; Animals; Benzamides; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Diphenylamine; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Silencing; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice, Transgenic; Proto-Oncogene Proteins B-raf; Tumor Suppressor Protein p53 | 2015 |
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Topics: Adenocarcinoma; Animals; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Comparative Genomic Hybridization; Diphenylamine; ErbB Receptors; Exons; Genes, ras; Genotype; Humans; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Mutagenesis, Site-Directed; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2010 |
MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphenylamine; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Transgenic; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Respiratory Mucosa; Tumor Cells, Cultured | 2012 |
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Diphenylamine; Dose-Response Relationship, Drug; Heterozygote; Humans; Lung Neoplasms; Maximum Tolerated Dose; Mice; Mice, Mutant Strains; Mitogen-Activated Protein Kinase Kinases; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidines; TOR Serine-Threonine Kinases | 2012 |
Carcinogenicity of 3-methyl-2-naphthylamine and 3,2'-dimethyl-4-aminobiphenyl to the bladder and gastrointestinal tract of the Syrian golden hamster with atypical proliferative enteritis.
Topics: 2-Naphthylamine; Adenocarcinoma; Aminobiphenyl Compounds; Aniline Compounds; Animals; Carcinogens; Carcinoma, Transitional Cell; Cricetinae; Diphenylamine; Enteritis; Gastrointestinal Neoplasms; Male; Mesocricetus; Naphthalenes; Neoplasms, Experimental; Time Factors; Urinary Bladder Neoplasms | 1981 |
Prostate adenocarcinoma in rats: induction by 3,2'-dimethyl-4-aminobiphenyl.
Topics: Adenocarcinoma; Aminobiphenyl Compounds; Aniline Compounds; Animals; Carcinoma in Situ; Diphenylamine; Male; Prostatic Neoplasms; Rats; Rats, Inbred F344 | 1982 |